At IRIS we are we our passionate about our mission to end preventable blindness. The countless stories of the people we have helped, and knowing that there are millions more out there who we can help is what keeps us going.
We don’t seek validation and pats on the back, but when it comes, we won’t shy away either.
So when we learned that IRIS was the recipient of the 2016 New Product Innovation award in Diabetic Retinopathy in North America by Frost & Sullivan, we were obviously thrilled.
IRIS CEO Jason Crawford had the honor to attend the Frost & Sullivan awards ceremony in San Diego, CA, where he was in very impressive company with innovative organizations like GE, Philips and Intel also accepting awards.
According to Frost & Sullivan, “Recognizing IRIS’ ability to improve the quality of life of diabetic retinopathy patients, we applaud the unrivaled value that the company provides through its truly unique technology.”
We were also delighted when Frost explained why we were selected:
“The IRIS technology offers superior price-performance value through the development of products for diverse unmet therapeutic applications, while facilitating improved yet simplified screening of patients. Frost & Sullivan firmly believes that IRIS will be the new industry benchmark in the rapidly growing diabetic retinopathy market.”
As we kick-off 2016, we hope this award is the launching point for a year filled with increased awareness, detection and prevention of blindness for the many Americans who suffer from diabetic retinopathy.